[1] Nault JC, Cheng AL, Sangro B, et al. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol, 2020, 72(2):209-214.
[2] Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 1991,350:429-431.
[3] de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A,1998,95:8847-8851.
[4] Wang J, Chenivesse X, Henglein B,et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature, 1990, 343:555-557.
[5] Ally A, Balasundaram M, Carlsen R, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell, 2017, 169:1327-1341.
[6] Schwabe R, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol, 2020, 72(2):230-238.
[7] Bresnahan R, Ramarodi P, Heikenwalder M, et al. Novel patient-derived preclinical models of liver cancer. J Hepatol,2020, 72(2):239-249.
[8] Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol, 2019, 16:411-428.
[9] Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol,2020, 72(2):250-261.
[10] 鲁凤民.肝细胞癌的血清学诊断—挑战与希望.临床肝胆病杂志,2017,33(7):1262-1265.
[11] Yao MJ,Zhao JM,Lu FM. Serum Golgi protein 73 is not a valuable diagnostic marker for hepatocellular carcinoma. Hepatol Int,2017, 11(Suppl1) : s172-s173.
[12] 钱相君,曲春枫,鲁凤民. 肝癌肿瘤标记物在超声筛查监测早期肝细胞癌中的作用不可或缺.肝脏,2019,24(8):851-853.
[13] Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol , 2020, 72(2):262-276.
[14] Berardi G, Van Cleven S, Fretland ?A, et al. Evolution of laparoscopic liver surgery from innovation to implementation to mastery: perioperative and oncologic outcomes of 2,238 patients from 4 European specialized centers. Am Coll Surg, 2017, 225:639-649.
[15] Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Hepatology, 2018;69:1284-1293.
[16] Lai Q, Vitale A, Iesari S, et al. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology,2017,66:1910-1919.
[17] Palmer DH, Malagari K, Kulik LM. Role of loco-regional therapies in the wake of systemic therapy. J Hepatol,2020. In Press.
[18] Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomized placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol, 2017, 2:565-575.
[19] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis,2010,30:52-60.
[20] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018, 67:358-380.
[21] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, openlabel phase 2 trial. Lancet Oncol, 2018, 19:940-952.
[22] Cheng AL, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab(atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol, 2019, 30(Suppl 9).
[23] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018,378:158-168.
[24] Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol,2020, 72(2):342-352.
[25] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell,2012,21:504-516.
[26] Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol,2019,20:663-673.
[27] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med,2010,362:1273-1281.
[28] Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov,2017,7:943-962.
[29] Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma.Clin Oncol, 2018, 36:276-282.
[30] Abou-Alfa GK, et al. ClarIDHy: a global, phase 3, randomized, doubleblind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol,2019, 30(suppl_5):v851-v934. |
